Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion

Pharmacotherapy

Volumn 23, Issue 8, 2003, Pages 988-991

  Dandekar, Prachi K ^a   Maglio, Dana ^a   Sutherland, Christina A ^a   Nightingale, Charles H ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; MEROPENEM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-BACTERIAL AGENTS; CROSS-OVER STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; THIENAMYCINS; TIME FACTORS;

EID: 0041848660     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.8.988.32878     Document Type: Article

References (12)

1. Craig WA, Ebert S, Wantanabe Y. Differences in time above MIC (T>MIC) required for efficacy of beta-lactams in animal infection models [abstr]. In: Program and abstracts of the 33rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1993:135.
2. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992;36:2577-83.
3. AstraZeneca Pharmaceuticals. Merrem (meropenem) package insert. Wilmington, DE; 2001.
4. Patel RP, Cook SE. Stability of meropenem in intravenous solutions. Am J Health-Syst Pharm 1997;4:412-21.
5. Grant EM, Zhong M, Ambrose PG, Nicolau DP, Nightingale CH, Quintiliani R. Stability of meropenem in a portable infusion device in a cold pouch. Am J Health-Syst Pharm 2000;57:992-5.
6. Tam VH, Louie A, Drusano GL. Rational empiric dosing strategy of cefepime against Pseudomonas aeruginosa: integrating population pharmacokinetics, pharmacodynamics and microbiologic surveillance [abstr]. Pharmacotherapy 2001;21:1287.
7. Bui KQ, Ambrose PG, Nicolau DP, Lapin CD, Nightingale CH, Quintiliani RQ. Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients. Chemotherapy 2001;47:153-6.
8. Elkhaili H, Niedergang S, Pompei D, Linger L, Leveque D, Jehl, F. High-performance liquid chromatography assay for meropenem in serum. J Chromatogr B Biomed Sci Appl 1996;686:19-26.
9. Mouton JW, Touw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems. Clin Pharmacokinet 2000;39:185-201.
10. Mouton JW, Van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet 1995;28:275-86.
11. Pfaller MA, Jones RN. MYSTIC (meropenem yearly susceptibility test information collection) results from the Americas: resistance implications in the treatment of serious infections. J Antimicrob Chemother 2000;46(suppl T2):25-37.
12. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979; 67:608-16.